Results 11 to 20 of about 7,754 (200)
The novel TFEB agonist desloratadine ameliorates hepatic steatosis by activating the autophagy-lysosome pathway [PDF]
Frontiers in PharmacologyThe autophagy-lysosome pathway plays an essential role in promoting lipid catabolism and preventing hepatic steatosis in non-alcoholic fatty liver disease (NAFLD).
Jieru Lin +10 more
doaj +5 more sources
Biopharmaceutical classification of desloratadine – not all drugs are classified the easy way
Acta Pharmaceutica, 2020 The biopharmaceutical classification of drugs was designed as a basis for bio-waivers – a mechanism with the double ethical benefit of delivering new drug formulations to the market with less human testing and lower cost.
Berginc Katja +4 more
doaj +4 more sources
Upsala Journal of Medical Sciences, 2018 Objective: Desloratadine, a third-generation antihistamine, is claimed to cause fewer central nervous system (CNS) adverse drug reactions (ADRs) than antihistamines of the first- and second-generation.
Jeltje Boer +2 more
doaj +2 more sources
Desloratadine analysis: as a pharmaceutical preparation and after accelerating ageing [PDF]
Current Issues in Pharmacy and Medical Sciences, 2015 Desloratadine is a biologically active compound that is not described in the Polish Pharmacopoeia IX, hence, its study is particular important. The aim of this work was to establish a procedure for desloratadine analysis by way of HPTLC in combination ...
Bober Katarzyna +2 more
doaj +2 more sources
Renal Failure, 2020 Purpose To examine the effect of desloratadine on kidney ischemia-reperfusion (I/R) injury in albino Wistar male rats using biochemical and histopathological methods. Methods The treated with ischemia–reperfusion + 5 mg/kg desloratadine (IRD) group (n–6)
Huseyin Kocaturk +8 more
doaj +2 more sources
24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139] [PDF]
BMC Family Practice, 2002 Background Early studies with desloratadine demonstrated efficacy in treating seasonal allergic rhinitis (SAR). A dose-ranging study was conducted to characterize its 24-hour efficacy in patients with SAR.
Lorber Richard, Salmun Luis M
doaj +3 more sources
World Allergy Organization Journal, 2011 Background Allergic rhinitis (AR) affects up to 36% of the population in the Middle East Gulf States. The second-generation nonsedating antihistamine desloratadine has demonstrated safety and efficacy in the treatment of AR; however, few studies have ...
Tamer M.H. Adham, MD(Pediatrics), MRCPCH(London)
doaj +2 more sources
Desloratadine Therapy Improves Allergic Rhinitis Symptoms in Latin American Children Aged 6 to 12 Years [PDF]
World Allergy Organization Journal, 2009 Objective To determine the effectiveness of desloratadine syrup in relieving symptoms of allergic rhinitis (AR) among children in Latin America.Methods In an open-label trial conducted in 5 Latin American countries, 455 children aged 6 to 12 years with ...
Paolo Tassinari +6 more
doaj +2 more sources
Improved survival in several cancers with use of H1-antihistamines desloratadine and loratadine
Translational Oncology, 2021 Background: We have previously shown an association with substantially improved survival in breast cancer and melanoma for desloratadine and loratadine users, and set out to find whether an improved survival can be seen in tumors with and without a known
Ildikó Fritz +2 more
doaj +2 more sources
Pakistan Journal of Pharmaceutical Sciences, 2022 To investigate the efficacy of desloratadine citrate combined with compound glycyrrhizin in the treatment of subacute eczema. 100 patients with subacute eczema who were admitted in our hospital from June 2019 to June 2020 were selected according to the ...
Gang Wang +4 more
doaj +2 more sources